Imugene Limited (IMU.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.036 (+2.86%) as of
Key statistics
- Market cap
- 19.95M
- Forward P/E
- -0.93
- EPS (TTM)
- -0.2900
- Dividend yield
- 0.00%
- 52-week range
- 0.0320 – 0.4300
- Beta
- 2.24
- Revenue (TTM)
- 2.09M
- Profit margin
- 0.00%
- Analyst target
- A$0.23
- Volume
- 875.61k
About Imugene Limited
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and Neo-POLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Sydney, NSW, Australia
- Employees
- 14
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.